HHC
CORT icon

Hutchin Hill Capital’s Corcept Therapeutics CORT Stock Holding History

Hutchin Hill Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-86,900
Closed -$631K – 912
2016
Q4 		$631K Buy
+86,900
New +$681K 0.02% 553
2016
Q3 		– Sell
-13,200
Closed -$72K – 615
2016
Q2 		$72K Buy
+13,200
New +$68.7K ﹤0.01% 502

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Hutchin Hill Capital's CORT Position: Q1 2017 in Review

Hutchin Hill Capital sold out of Corcept Therapeutics (CORT) in Q1 2017, closing a stake of 86,900 shares — an estimated $631K sold.

Hutchin Hill Capital first reported a position in CORT in Q2 2016 and held it in 2 quarters. The position peaked at $631K in Q4 2016. 135 funds tracked by Wall St. Rank hold CORT as of Q1 2017.

  • Hutchin Hill Capital reported no remaining Corcept Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Hutchin Hill Capital sold 86,900 Corcept Therapeutics shares in Q1 2017, an estimated $631K.
  • Hutchin Hill Capital first reported a position in Corcept Therapeutics in Q2 2016 and held it in 2 quarters.
  • Hutchin Hill Capital's Corcept Therapeutics position peaked at $631K in Q4 2016.
  • 135 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2017.

Based on Hutchin Hill Capital's 13F filing for Q1 2017, filed 15 May 2017.